BMXMF (BioMerieux) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMXMF BioMerieux SA BMXMF
67 GF Score
Price $80.52
GF Value $127.87
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BMXMF
67GF Score
BioMerieux SA BMXMF
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (BMXMF) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of $80.52 is trading 37% below its estimated GF Value™ of $127.87. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for BMXMF:

  • Short Ratio:
  • GF Value™: $127.87 vs. price of $80.52 (37% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BMXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
67GF Score

Get the complete analysis for BMXMF

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.52
Price
$127.87
GF Value